G62.0
Conditions
Interventions
Group 1: Ten acupuncture treatments during the first study period. Nerve conduction studies (NCS) are performed before and after the treatment period. In the second study period, patients do not recei
Sponsors
HanseMerkur Versicherungsgesellschaft
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Clinically diagnosed chemotherapy-induced peripheral neuropathy, pathologic results of the sural nerve in nerve conduction studies
Exclusion criteria
Exclusion criteria: Current chemotherapy treatment or restart of chemotherapy due to tumor recurrence; Other diseases hat may cause peripheral neuropathy; History of epilepsy; Coagulopathy or use of anticoagulants with bleeding time > 3 min, prothrombin time 50 sec; Bacterial infection or other skin diseases at the lower extremities; Bone fracture of the lower extremities during the last three months; Alcohol, opiat, analgetic, or drug abuse; Psychiatric illnesses other than mild depression; Incapacity of following the study instructions ;(severe language disturbances, serious cognitive deficits, lack of time); Pregnant or breast-feeding women; Current participation in other clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensory sural nerve action potential amplitude (SNAP) as measured by nerve conduction studies. Evaluation at baseline, at week 14 after treatment or wait list period, and at week 28 after wait list period or treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Motor tibial nerve action potential amplitude, sural and tibial nerve conduction velocity as measured by nerve conduction studies, Total Neuropathy Score, symptom related NRS questionnaire. Evaluation time points as for the primary endpoint | — |
Countries
Germany
Contacts
Public ContactSven Schroeder
HanseMerkur Zentrum für Traditionelle Chinesische Medizin am Universitätsklinikum Hamburg-Eppendorf
Outcome results
None listed